Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

U.K.-based Mallinckrodt plc halted its Phase IIB amyotrophic lateral sclerosis (ALS) trial after the study’s Independent Data and Safety Monitoring Board recommended the trial be halted due to concerns over patients developing pneumonia who were using the company’s investigational treatment.